Paper published in a journal (Scientific congresses and symposiums)
Third-party mesenchymal stem cell infusion in kidney transplant recipient: 6-month safety interim analysis
WEEKERS, Laurent; ERPICUM, Pauline; DETRY, Olivier et al.
2015In Transplant International, 28 (S4), p. 223-224/BO278
Peer Reviewed verified by ORBi
 

Files


Full Text
BO278.pdf
Publisher postprint (136.74 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Organ transplantation
Abstract :
[en] Background: Mesenchymal stromal cell (MSC) have immunomodulating properties and could be used as immunosuppressive agents. We report the 6- month safety results for the 5 first patients treated with MSC after kidney transplantation (KTx). Here, we address 3 specific safety issues: immunization against MSC and engraftment syndrome defined as acute graft dysfunction not related to rejection and over-immunosuppression. Patients and method: MSC production was carried out locally. MSC were not matched with kidney recipients’ HLA. Included patients were non-immunized, first transplant recipients from deceased donors. MSC (1.5–3.0 9 106/kg) infusion was planned 3 to 5 days post KTx. Patients with cardiovascular instability post KTx were excluded. All patients were treated with Basiliximab induction, Tacrolimus, Mycophenolate Mofetil and Steroid. We prospectively screened for anti-HLA antibodies at month 1, 3 and 6. Informed consent was obtained from all participants. The local ethical committee approved the protocol. Results: Collectively there were 23/50 and 29/50 HLA mismatches (MM) with kidney and MSC donor respectively, out of which 5 were shared MM. One patient developed de novo DSA, 2 patients anti-HLA antibodies against shared kidney/MSC MM and 1 patient developed 2 specific antibodies against MSC (MSCSA) at month 6. All antibodies were anti HLA class I except for 1. We did not observe any “engraftment” syndrome. Three patients experienced non- severe opportunistic infections: 1 CMV reactivation and 2 polyoma-BK virus viremia.Conclusion: We did not observe any strong safety signal. We did however observe some degree of immunization in 3 patients: 2 developed antibodies against shared kidney/MSC donor HLA MM and 1 MSCSA.
Disciplines :
Surgery
Hematology
Urology & nephrology
Author, co-author :
WEEKERS, Laurent  ;  Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
ERPICUM, Pauline ;  Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
DETRY, Olivier  ;  Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
JOURET, François  ;  Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
LECHANTEUR, Chantal ;  Centre Hospitalier Universitaire de Liège - CHU > Thérapie cellulaire
DELBOUILLE, Marie-Hélène ;  Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
BRIQUET, Alexandra ;  Centre Hospitalier Universitaire de Liège - CHU > Centre d'oncologie
BAUDOUX, Etienne  ;  Centre Hospitalier Universitaire de Liège - CHU > Thérapie cellulaire
BEGUIN, Yves  ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Third-party mesenchymal stem cell infusion in kidney transplant recipient: 6-month safety interim analysis
Publication date :
November 2015
Event name :
The International Transplant Congress - Brussels 2015
Event organizer :
European Society for Organ Transplantation (ESOT)
Event place :
Brussels, Belgium
Event date :
du 13 au 16 septembre 2015
Audience :
International
Journal title :
Transplant International
ISSN :
0934-0874
eISSN :
1432-2277
Publisher :
Springer International, Heidelberg, Germany
Volume :
28
Issue :
S4
Pages :
223-224/BO278
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 30 December 2015

Statistics


Number of views
91 (18 by ULiège)
Number of downloads
84 (5 by ULiège)

Bibliography


Similar publications



Contact ORBi